Jubilant Life Sciences Limited said late on Wednesday its new drug aimed at treating prostate cancer is expected to enter clinical trials by the end of this year in the United States.
US based Endo Pharmaceuticals Inc and Jubilant's Bangalore unit are jointly developing the drug. The US Food and Drug Administration has accepted the filing for this investigational new drug application, Jubilant said in a statement.
【News source】
Jubilant Life sees cancer drug trials by end-2013
Your Comments